Circio Holding ASA

Circio Holding ASA: Requested Conversion of Convertible Bonds

Reference is made to Circio Holding ASA's (the "Company") outstanding

convertible bonds as issued to Atlas Special Opportunities, LLC ("Atlas") under

the Investment Agreement entered into between Atlas and the Company in March

Atlas has, by a notice of conversion, requested conversion of convertible bonds

with a nominal value of NOK 2,500,000 which, pursuant to the bond terms, are

convertible into 3,931,847 new shares in the Company at a conversion price of

NOK 0.6358.

The Company's share capital will accordingly be increased by NOK 2,359,108.20 by

the issuance of 3,931,847 new shares upon completion of the conversion by

registration of the share capital increase in the Norwegian Register of Business

Enterprises (Nw.: Foretaksregisteret). Following the conversion, the Company's

total share capital will be NOK 56,845,650.60 divided into 94,742,751 shares,

each with a nominal value of NOK 0.60.

For further information, please contact:

Erik Digman Wiklund, CEO

Phone: +47 413 33 536

Lubor Gaal, CFO

Phone: +34 683343811

About Circio

Building next generation RNA technology for nucleic acid medicine

Circio Holding ASA is a biotechnology company developing powerful circular RNA

vector expression technology for next generation nucleic acid medicine. Circio

has established a unique circular RNA (circRNA) vector expression platform for

novel DNA, RNA and viral therapeutics. The proprietary circVec technology is

based on a modular genetic cassette design for efficient biogenesis of

multifunctional circRNA inside cells, which can be deployed in multiple

therapeutic settings, including genetic medicine, cell therapy and chronic

disease. The circVec platform has demonstrated up to 15-fold enhanced and more

significantly more durable protein expression vs. classic mRNA vector systems

and has the potential to become a new gold-standard platform technology for

nucleic acid and viral therapeutics in the future. The circRNA R&D activities

are being conducted by the wholly owned subsidiary Circio AB based at the

Karolinska Institute in Stockholm, Sweden.

In addition, Circio is developing a pan-RAS cancer vaccine, TG01, targeting KRAS

driver mutations. TG01 is currently being tested in two clinical trials: RAS

-mutated pancreatic and lung cancer in the USA and multiple myeloma in Norway.

These studies are being run through academic and industry collaborative

networks, supported by prestigious research grants from Innovation Norway and

the Norwegian Research Council, creating read-outs and future optionality for

the program at low cost to Circio.

AI Terminal